サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1276458

多発性骨髄腫の世界市場規模、シェア、産業動向分析レポート：エンドユーザー別、疾患タイプ別（症候性多発性骨髄腫、くすぶり型（無症候性）多発性骨髄腫）、薬剤タイプ別、地域別展望・予測、2023～2029年

Global Multiple Myeloma Market Size, Share & Industry Trends Analysis Report By End User, By Disease Type (Active Multiple Myeloma and Smoldering Multiple Myeloma), By Drug Type, By Regional Outlook and Forecast, 2023 - 2029
出版日: | 発行: KBV Research | ページ情報: 英文 213 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
多発性骨髄腫の世界市場規模、シェア、産業動向分析レポート：エンドユーザー別、疾患タイプ別（症候性多発性骨髄腫、くすぶり型（無症候性）多発性骨髄腫）、薬剤タイプ別、地域別展望・予測、2023～2029年
出版日: 2023年04月28日
発行: KBV Research
ページ情報: 英文 213 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

多発性骨髄腫市場規模は、2029年には375億米ドルに達し、予測期間中にCAGR9.8%の市場成長率で上昇すると予測されています。

多発性骨髄腫は、悪性腫瘍を発症し、制御不能なまでに増殖している形質細胞を指す言葉です。モノクローナル免疫グロブリン、またはMタンパク質、Mスパイク、パラプロテインは、形質細胞が作り出す異常なタンパク質（抗体）です。健康な形質細胞が作る免疫グロブリンは、細菌を認識して排除することができるので、感染症との戦いに有効です。

しかし、多発性骨髄腫の患者さんの骨髄にはがん化した形質細胞が集まり、健康な血球を破壊します。その結果、体内でパラプロテインという異常なタンパク質が生成され、それが蓄積して組織や臓器に害を及ぼす可能性があります。多発性骨髄腫には、頻繁な感染症、貧血、骨の痛み、腎臓の問題など、いくつかの副作用があります。治療の選択肢として、標的療法、化学療法、放射線療法、幹細胞移植があります。

COVID-19影響度分析

パンデミックにより研究開発業務に大きな支障をきたしたため、多発性骨髄腫の新薬や治療法の開発も大幅に遅れました。さらに、2021年12月のBlood Cancer Journalによると、2020年に新たに確認された多発性骨髄腫の症例は2019年と比較して少なく、その症例の生存率も同時に低下しています。多発性骨髄腫の患者は、2020年に死亡率とCOVID-19感染リスクが高くなっています。したがって、パンデミックは多発性骨髄腫市場に有害な影響を及ぼしました。

市場の成長要因

世界的に増加する政府支援の取り組み

政府および組織は、医療行為と並行して、医療提供者との関係で現在発生している他の問題（料金体系と償還、医療施設、薬剤投与経路、政治、および他のネットワーク問題など）についても支援を拡大しています。これらの問題は、プライマリケア医が専門医や他の専門家とケアを調整する患者ケア型医療施設の受け入れや、商業施設とメディケア/メディケイドの両方の領域で安価な腫瘍医療機関の設立など、腫瘍診療をより多くの支払者と提供者の共同イニシアチブへと押し上げつつあります。したがって、政府による支援の増加は、多発性骨髄腫の治療薬や薬剤の需要を増加させ、市場の拡大に拍車をかけると予測されます。

世界の多発性骨髄腫の症例の増加

多発性骨髄腫を含むいくつかの種類の血液悪性腫瘍の発生率が上昇していることは、市場を牽引する主要な要因の1つです。多発性骨髄腫は珍しいがんの一種と考えられていますが、世界中でかなりの数のがん患者がおり、効果的で最先端の治療法に対する需要が高まっています。効果的な最先端治療が行われることで、患者さんはより良い臨床結果を得ることができます。このことは、MMの有病率が世界的に増加する傾向にあることから、極めて重要です。また、研究開発の結果、治療法が進歩し、予後を改善するために、より複雑な医薬品が必要になっています。

市場抑制要因

永久的な解決策がなく、多くの既存の治療法に副作用がある

カイプロリスの一般的な副作用には、疲労、血球数と血小板数の低下、下痢、便秘、吐き気、息切れ、発熱、四肢の腫れ、上気道感染、気管支炎、肺炎があります。さらに、特定の副作用として、血中カリウムの低下、高血糖、血中カルシウムの低下、筋肉の痙攣、四肢のしびれや麻痺、高血圧などがあります。また、放射線療法では、疲労、皮膚の炎症、吐き気、下痢、治療部位の脱毛、不妊症、感染症のリスクの上昇、食欲不振、その後のがんのリスクの上昇、治療部位近傍の臓器への害などの副作用があります。

薬剤タイプの展望

薬剤タイプにより、多発性骨髄腫市場は化学療法、プロテアーゼ阻害剤、モノクローナル抗体、その他に分類されます。モノクローナル抗体セグメントは、2022年の多発性骨髄腫市場でかなりの成長率を調達しました。多発性骨髄腫の治療選択肢は、近年のモノクローナル抗体（mAb）の導入により、根本的に変化しました。再発・難治性患者に対するエロツズマブやダラツムマブの有効性は、この疾患に対するmAbに多くの関心を呼び起こしました。

エンドユーザーの展望

エンドユーザー別に見ると、多発性骨髄腫市場は病院、診療所、その他に分けられます。病院セグメントは、2022年の多発性骨髄腫市場において最大の収益シェアを獲得しました。病院セグメントは、患者の入院数の増加、多発性骨髄腫の有病率の上昇、患者サービスの向上を可能にするこれらの施設に有能な医療スタッフがいることなどの要因によって成長しています。治療に使用される薬剤が病院で日常的に処方され、投与されるという事実が、このセグメントの優位性のかなりの部分を占めています。

疾患タイプ別の展望

多発性骨髄腫市場は、疾患タイプによって症候性多発性骨髄腫とくすぶり型（無症候性）多発性骨髄腫に分類されます。2022年の多発性骨髄腫市場では、くすぶり型（無症候性）多発性骨髄腫のセグメントが顕著な成長率を獲得しました。このセグメントの成長は、この病気に対する認識の高まりに起因しています。くすぶり型（無症候性）多発性骨髄腫は、活動型になるまでに数年かかることがあります。その結果、この症候群を持つ人の中には、症候性のMMを経験しない人もいます。ヘルスケア専門家は、症候性多発性骨髄腫に移行しつつある症状を観察することで、SMMをコントロールします。

地域別展望

地域別に見ると、多発性骨髄腫市場は、北米、欧州、アジア太平洋、LAMEAで分析されています。北米セグメントは、2022年に多発性骨髄腫市場で最も高い収益シェアを調達しました。主要な競合他社の存在感が強く、多発性骨髄腫薬の発売や製品承認の増加により、北米の多発性骨髄腫市場は予測期間中に大きく拡大すると予測されます。さらに、多発性骨髄腫の有病率が上昇していることから、市場の発展が予想されています。例えば、米国がん協会は、2023年までに米国で35,730件の多発性骨髄腫の発生が発見されると予測しています。

市場参入企業がとる主な戦略は、買収です。カーディナルマトリックスで提示された分析に基づくと、Novartis AG、Johnson &Johnson、Pfizer, Inc.が多発性骨髄腫市場の先駆者です。Amgen, Inc.、Sanofi S.A.、Bristol Myers Squibb Companyなどの企業は、多発性骨髄腫市場における主要な革新者の一部です。

目次

第1章 市場範囲と調査手法

  • 市場の定義
  • 目的
  • 市場範囲
  • セグメンテーション
    • 世界の多発性骨髄腫市場：エンドユーザー別
    • 世界の多発性骨髄腫市場：疾患タイプ別
    • 世界の多発性骨髄腫市場：薬剤タイプ別
    • 世界の多発性骨髄腫市場：地域別
  • 調査手法

第2章 市場概要

  • イントロダクション
    • 概要
      • 市場構成とシナリオ
  • 市場に影響を与える主な要因
    • 市場促進要因
    • 市場抑制要因

第3章 競合分析- 世界

  • KBVカーディナルマトリックス
  • 最近の業界全体の戦略的展開
    • パートナーシップ、コラボレーション、および契約
    • 製品の発売と製品の拡大
    • 買収と合併
    • 試験と承認
  • 主要成功戦略
    • 主要なリーディングストラテジー

第4章 世界の多発性骨髄腫市場：エンドユーザー別

  • 世界の病院市場：地域別
  • 世界のクリニック市場：地域別
  • 世界のその他の市場：地域別

第5章 世界の多発性骨髄腫市場：疾患タイプ別

  • 世界の症候性多発性骨髄腫市場：地域別
  • 世界のくすぶり型（無症候性）多発性骨髄腫市場：地域別

第6章 世界の多発性骨髄腫市場：薬剤タイプ別

  • 世界のプロテアーゼ阻害剤市場：地域別
  • 世界のモノクローナル抗体市場：地域別
  • 世界の化学療法市場：地域別
  • 世界のその他の市場：地域別

第7章 世界の多発性骨髄腫市場：地域別

  • 北米
    • 北米の市場：国別
      • 米国
      • カナダ
      • メキシコ
      • その他北米地域
  • 欧州
    • 欧州の市場：国別
      • ドイツ
      • 英国
      • フランス
      • ロシア
      • スペイン
      • イタリア
      • その他欧州地域
  • アジア太平洋
    • アジア太平洋の市場：国別
      • 中国
      • 日本
      • インド
      • 韓国
      • シンガポール
      • マレーシア
      • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ラテンアメリカ・中東・アフリカの市場：国別
      • ブラジル
      • アルゼンチン
      • アラブ首長国連邦
      • サウジアラビア
      • 南アフリカ
      • ナイジェリア
      • その他ラテンアメリカ・中東・アフリカ地域

第8章 企業プロファイル

  • Johnson & Johnson
  • Novartis AG
  • Sanofi SA
  • Amgen, Inc
  • AbbVie, Inc
  • Baxter International, Inc
  • Teva Pharmaceutical Industries Ltd
  • Pfizer, Inc
  • Bristol Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
図表

LIST OF TABLES

  • TABLE 1 Global Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 2 Global Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Multiple Myeloma Market
  • TABLE 4 Product Launches And Product Expansions- Multiple Myeloma Market
  • TABLE 5 Acquisition and Mergers- Multiple Myeloma Market
  • TABLE 6 Trials and approvals - Multiple Myeloma Market
  • TABLE 7 Global Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 8 Global Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 9 Global Hospitals Market by Region, 2019 - 2022, USD Million
  • TABLE 10 Global Hospitals Market by Region, 2023 - 2029, USD Million
  • TABLE 11 Global Clinics Market by Region, 2019 - 2022, USD Million
  • TABLE 12 Global Clinics Market by Region, 2023 - 2029, USD Million
  • TABLE 13 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 14 Global Others Market by Region, 2023 - 2029, USD Million
  • TABLE 15 Global Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 16 Global Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 17 Global Active Multiple Myeloma Market by Region, 2019 - 2022, USD Million
  • TABLE 18 Global Active Multiple Myeloma Market by Region, 2023 - 2029, USD Million
  • TABLE 19 Global Smoldering Multiple Myeloma Market by Region, 2019 - 2022, USD Million
  • TABLE 20 Global Smoldering Multiple Myeloma Market by Region, 2023 - 2029, USD Million
  • TABLE 21 Global Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 22 Global Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 23 Global Protease Inhibitors Market by Region, 2019 - 2022, USD Million
  • TABLE 24 Global Protease Inhibitors Market by Region, 2023 - 2029, USD Million
  • TABLE 25 Global Monoclonal Antibody Market by Region, 2019 - 2022, USD Million
  • TABLE 26 Global Monoclonal Antibody Market by Region, 2023 - 2029, USD Million
  • TABLE 27 Global Chemotherapy Market by Region, 2019 - 2022, USD Million
  • TABLE 28 Global Chemotherapy Market by Region, 2023 - 2029, USD Million
  • TABLE 29 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 30 Global Others Market by Region, 2023 - 2029, USD Million
  • TABLE 31 Global Multiple Myeloma Market by Region, 2019 - 2022, USD Million
  • TABLE 32 Global Multiple Myeloma Market by Region, 2023 - 2029, USD Million
  • TABLE 33 North America Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 34 North America Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 35 North America Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 36 North America Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 37 North America Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 38 North America Hospitals Market by Country, 2023 - 2029, USD Million
  • TABLE 39 North America Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 40 North America Clinics Market by Country, 2023 - 2029, USD Million
  • TABLE 41 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 42 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 43 North America Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 44 North America Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 45 North America Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 46 North America Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 47 North America Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 48 North America Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 49 North America Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 50 North America Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 51 North America Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 52 North America Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 53 North America Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
  • TABLE 54 North America Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
  • TABLE 55 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 56 North America Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 57 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 58 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 59 North America Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 60 North America Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 61 US Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 62 US Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 63 US Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 64 US Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 65 US Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 66 US Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 67 US Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 68 US Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 69 Canada Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 70 Canada Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 71 Canada Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 72 Canada Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 73 Canada Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 74 Canada Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 75 Canada Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 76 Canada Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 77 Mexico Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 78 Mexico Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 79 Mexico Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 80 Mexico Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 81 Mexico Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 82 Mexico Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 83 Mexico Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 84 Mexico Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 85 Rest of North America Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 86 Rest of North America Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 87 Rest of North America Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 88 Rest of North America Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 89 Rest of North America Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 90 Rest of North America Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 91 Rest of North America Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 92 Rest of North America Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 93 Europe Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 94 Europe Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 95 Europe Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 96 Europe Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 97 Europe Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 98 Europe Hospitals Market by Country, 2023 - 2029, USD Million
  • TABLE 99 Europe Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 100 Europe Clinics Market by Country, 2023 - 2029, USD Million
  • TABLE 101 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 102 Europe Others Market by Country, 2023 - 2029, USD Million
  • TABLE 103 Europe Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 104 Europe Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 105 Europe Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 106 Europe Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 107 Europe Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 108 Europe Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 109 Europe Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 110 Europe Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 111 Europe Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 112 Europe Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 113 Europe Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
  • TABLE 114 Europe Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
  • TABLE 115 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 116 Europe Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 117 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 118 Europe Others Market by Country, 2023 - 2029, USD Million
  • TABLE 119 Europe Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 120 Europe Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 121 Germany Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 122 Germany Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 123 Germany Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 124 Germany Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 125 Germany Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 126 Germany Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 127 Germany Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 128 Germany Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 129 UK Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 130 UK Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 131 UK Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 132 UK Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 133 UK Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 134 UK Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 135 UK Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 136 UK Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 137 France Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 138 France Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 139 France Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 140 France Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 141 France Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 142 France Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 143 France Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 144 France Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 145 Russia Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 146 Russia Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 147 Russia Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 148 Russia Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 149 Russia Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 150 Russia Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 151 Russia Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 152 Russia Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 153 Spain Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 154 Spain Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 155 Spain Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 156 Spain Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 157 Spain Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 158 Spain Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 159 Spain Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 160 Spain Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 161 Italy Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 162 Italy Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 163 Italy Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 164 Italy Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 165 Italy Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 166 Italy Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 167 Italy Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 168 Italy Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 169 Rest of Europe Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 170 Rest of Europe Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 171 Rest of Europe Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 172 Rest of Europe Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 173 Rest of Europe Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 174 Rest of Europe Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 175 Rest of Europe Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 176 Rest of Europe Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 177 Asia Pacific Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 178 Asia Pacific Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 179 Asia Pacific Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 180 Asia Pacific Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 181 Asia Pacific Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 182 Asia Pacific Hospitals Market by Country, 2023 - 2029, USD Million
  • TABLE 183 Asia Pacific Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 184 Asia Pacific Clinics Market by Country, 2023 - 2029, USD Million
  • TABLE 185 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 186 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
  • TABLE 187 Asia Pacific Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 188 Asia Pacific Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 189 Asia Pacific Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 190 Asia Pacific Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 191 Asia Pacific Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 192 Asia Pacific Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 193 Asia Pacific Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 194 Asia Pacific Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 195 Asia Pacific Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 196 Asia Pacific Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 197 Asia Pacific Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
  • TABLE 198 Asia Pacific Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
  • TABLE 199 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 200 Asia Pacific Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 201 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 202 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
  • TABLE 203 Asia Pacific Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 204 Asia Pacific Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 205 China Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 206 China Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 207 China Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 208 China Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 209 China Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 210 China Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 211 China Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 212 China Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 213 Japan Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 214 Japan Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 215 Japan Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 216 Japan Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 217 Japan Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 218 Japan Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 219 Japan Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 220 Japan Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 221 India Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 222 India Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 223 India Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 224 India Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 225 India Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 226 India Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 227 India Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 228 India Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 229 South Korea Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 230 South Korea Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 231 South Korea Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 232 South Korea Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 233 South Korea Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 234 South Korea Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 235 South Korea Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 236 South Korea Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 237 Singapore Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 238 Singapore Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 239 Singapore Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 240 Singapore Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 241 Singapore Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 242 Singapore Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 243 Singapore Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 244 Singapore Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 245 Malaysia Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 246 Malaysia Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 247 Malaysia Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 248 Malaysia Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 249 Malaysia Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 250 Malaysia Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 251 Malaysia Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 252 Malaysia Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 253 Rest of Asia Pacific Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 254 Rest of Asia Pacific Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 255 Rest of Asia Pacific Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 256 Rest of Asia Pacific Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 257 Rest of Asia Pacific Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 258 Rest of Asia Pacific Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 259 Rest of Asia Pacific Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 260 Rest of Asia Pacific Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 261 LAMEA Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 262 LAMEA Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 263 LAMEA Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 264 LAMEA Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 265 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 266 LAMEA Hospitals Market by Country, 2023 - 2029, USD Million
  • TABLE 267 LAMEA Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 268 LAMEA Clinics Market by Country, 2023 - 2029, USD Million
  • TABLE 269 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 270 LAMEA Others Market by Country, 2023 - 2029, USD Million
  • TABLE 271 LAMEA Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 272 LAMEA Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 273 LAMEA Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 274 LAMEA Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 275 LAMEA Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 276 LAMEA Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 277 LAMEA Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 278 LAMEA Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 279 LAMEA Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 280 LAMEA Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 281 LAMEA Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
  • TABLE 282 LAMEA Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
  • TABLE 283 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 284 LAMEA Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 285 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 286 LAMEA Others Market by Country, 2023 - 2029, USD Million
  • TABLE 287 LAMEA Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 288 LAMEA Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 289 Brazil Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 290 Brazil Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 291 Brazil Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 292 Brazil Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 293 Brazil Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 294 Brazil Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 295 Brazil Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 296 Brazil Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 297 Argentina Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 298 Argentina Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 299 Argentina Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 300 Argentina Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 301 Argentina Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 302 Argentina Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 303 Argentina Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 304 Argentina Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 305 UAE Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 306 UAE Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 307 UAE Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 308 UAE Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 309 UAE Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 310 UAE Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 311 UAE Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 312 UAE Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 313 Saudi Arabia Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 314 Saudi Arabia Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 315 Saudi Arabia Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 316 Saudi Arabia Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 317 Saudi Arabia Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 318 Saudi Arabia Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 319 Saudi Arabia Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 320 Saudi Arabia Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 321 South Africa Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 322 South Africa Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 323 South Africa Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 324 South Africa Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 325 South Africa Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 326 South Africa Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 327 South Africa Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 328 South Africa Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 329 Nigeria Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 330 Nigeria Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 331 Nigeria Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 332 Nigeria Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 333 Nigeria Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 334 Nigeria Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 335 Nigeria Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 336 Nigeria Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 337 Rest of LAMEA Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 338 Rest of LAMEA Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 339 Rest of LAMEA Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 340 Rest of LAMEA Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 341 Rest of LAMEA Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 342 Rest of LAMEA Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 343 Rest of LAMEA Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 344 Rest of LAMEA Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 345 Key information -Johnson & Johnson
  • TABLE 346 Key Information - Novartis AG
  • TABLE 347 Key Information - Sanofi S.A.
  • TABLE 348 Key Information - Amgen, Inc.
  • TABLE 349 Key information - AbbVie, Inc.
  • TABLE 350 Key Information - Baxter International, Inc.
  • TABLE 351 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 352 Key Information - Pfizer, Inc.
  • TABLE 353 Key Information - Bristol Myers Squibb Company
  • TABLE 354 Key Information - Takeda Pharmaceutical Company Limited

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
  • FIG 4 Global Multiple Myeloma Market share by End User, 2022
  • FIG 5 Global Multiple Myeloma Market share by End User, 2029
  • FIG 6 Global Multiple Myeloma Market by End User, 2019 - 2029, USD Million
  • FIG 7 Global Multiple Myeloma Market share by Disease Type, 2022
  • FIG 8 Global Multiple Myeloma Market share by Disease Type, 2029
  • FIG 9 Global Multiple Myeloma Market by Disease Type, 2019 - 2029, USD Million
  • FIG 10 Global Multiple Myeloma Market share by Drug Type, 2022
  • FIG 11 Global Multiple Myeloma Market share by Drug Type, 2029
  • FIG 12 Global Multiple Myeloma Market by Drug Type, 2019 - 2029, USD Million
  • FIG 13 Global Multiple Myeloma Market share by Region, 2022
  • FIG 14 Global Multiple Myeloma Market share by Region, 2029
  • FIG 15 Global Multiple Myeloma Market by Region, 2019 - 2029, USD Million
  • FIG 16 SWOT analysis: Johnson & Johnson
  • FIG 17 Recent strategies and developments: Novartis AG
  • FIG 18 Recent strategies and developments: Sanofi S.A.
目次

The Global Multiple Myeloma Market size is expected to reach $37.5 billion by 2029, rising at a market growth of 9.8% CAGR during the forecast period.

Multiple myeloma or plasma cell cancer is a disease. The immune system is significantly dependent on healthy plasma cells, which are located in the bone marrow. In order to combat infections and other diseases, the immune system is composed of various cell types. T cells and B cells are two of the most common types of lymphocytes (lymph cells) in the immune system. The lymph nodes, bone marrow, intestines, and circulation are just a few of the organs where lymphocytes can be found.

B cells develop into plasma cells due to the immune system's response to an infection. Antibodies, also known as immunoglobulins, are produced by plasma cells and aid the body's defense against pathogens. Bone marrow contains the majority of plasma cells. Soft tissue found inside bones is called bone marrow. Other blood cells, including red, white, and platelets, are also found in the normal bone marrow and plasma cells.

Multiple myeloma is the term used to describe plasma cells that have developed malignancy and are growing uncontrollably. Monoclonal immunoglobulin, or M-protein, M-spike, or paraprotein, is an aberrant protein (antibody) produced by plasma cells. Immunoglobulins made by healthy plasma cells can recognize and eliminate germs, which is helpful in the fight against infections.

However, cancerous plasma cells gather in the bone marrow of patients with multiple myeloma and destroy healthy blood cells. As a result, the body produces paraproteins, aberrant proteins that can accumulate and harm tissues and organs. Multiple myeloma has several side effects, including frequent infections, anemia, bone pain, and renal problems. Targeted therapy, chemotherapy, radiation therapy, and stem cell transplantation are available as alternatives for treatment.

COVID-19 Impact Analysis

Since R&D operations were substantially hampered by the pandemic, developing novel medicines and treatments for multiple myeloma also slowed considerably. Moreover, the Blood Cancer Journal reported in December 2021 that fewer new instances of multiple myeloma were identified in 2020 in comparison with 2019 and that the survival rate for those cases declined concurrently. Patients with multiple myeloma had a higher mortality rate and COVID-19 infection risk in 2020. Therefore, the pandemic had a detrimental effect on the multiple myeloma market.

Market Growth Factors

Increasing government support initiatives worldwide

Along with care practices, governments and organizations are also extending support for other current problems in provider relations include fee schedules & reimbursement, sites of care, route of drug administration, and politics as well as other network issues. These problems are pushing oncology practices into more payer-provider collaborative initiatives, including accepting patient-care medical homes, where primary care doctors coordinate care with experts and other specialists and creating affordable oncology healthcare institutions in both the commercial and Medicare/Medicaid spaces. Hence, the increasing support of governments is projected to increase demand for treatments or medications for multiple myeloma, thereby fueling market expansion.

Rising cases of multiple myeloma worldwide

The rising incidence of several types of blood malignancies, including multiple myeloma, is one of the major market-driving factors. Although MM is regarded as a more uncommon cancer kind, there are a sizable number of cases of cancer worldwide, and the demand for effective and cutting-edge therapies is rising. Patients frequently experience better and more favorable clinical results when effective and cutting-edge therapies are administered. This is crucial because current trends point to an increase in the prevalence of MM around the globe. In addition, as a result of ongoing R&D, treatment has advanced, necessitating more complex medicines to improve prognosis.

Market Restraining Factors

Lack of permanent solutions and side effects of many existing treatments

Common side effects of Kyprolis include fatigue, a low blood cell count and blood platelet levels, diarrhea, constipation, nausea, shortness of breath, fever, swelling of the extremities, upper respiratory tract infection, bronchitis, and pneumonia. Additionally, certain side effects of the drug include low blood potassium, high blood sugar, low blood calcium, muscle spasms, numbness and tingling in the extremities, and high blood pressure. In addition, radiation therapy can cause adverse effects such as fatigue, irritation of the skin, nausea, diarrhea, loss of hair in the treatment area, infertility, higher risk of infection, loss of appetite, increased risk of subsequent cancer, and harm to organs located near the treatment area.

Drug Type Outlook

Based on drug type, the multiple myeloma market is categorized into chemotherapy, protease inhibitors, monoclonal antibody, and others. The monoclonal antibodies segment procured a considerable growth rate in the multiple myeloma market in 2022. The therapeutic options for multiple myeloma have radically changed due to the recent introduction of monoclonal antibodies (mAbs). The effectiveness of elotuzumab and daratumumab in relapsed/refractory patients has sparked much interest in mAbs for this condition.

End User Outlook

On the basis of end user, the multiple myeloma market is divided into hospitals, clinics, and others. The hospitals segment acquired the largest revenue share in the multiple myeloma market in 2022. The hospital segment is growing due to factors including an increase in patient admissions, a rise in the prevalence of multiple myeloma, and the availability of qualified medical staff in these facilities that enable improved patient services. The fact that the medications used in treatment can be routinely prescribed and given in hospital settings accounts for a significant portion of this segment's dominance.

Disease Type Outlook

Based on disease type, the multiple myeloma market is segmented into active multiple myeloma and smoldering multiple myeloma. The smoldering multiple myeloma segment garnered a remarkable growth rate in the multiple myeloma market in 2022. The growth of the segment is owed to the increasing awareness of the disease. It may take years for smoldering multiple myeloma to develop into an active form. As a result, some individuals with this syndrome never experience active MM. Healthcare professionals' control SMM by watching for symptoms that it's turning into active multiple myeloma.

Regional Outlook

On the basis of region, the multiple myeloma market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the multiple myeloma market in 2022. Due to the strong presence of key competitors and the rise in multiple myeloma drug launches and product approvals, the North American multiple myeloma market is predicted to expand considerably over the forecast period. Moreover, the market is anticipated to develop because of the rising prevalence of multiple myeloma. For instance, the American Cancer Society forecasted that by 2023, 35,730 incidences of multiple myeloma would have been discovered in the United States.

The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Novartis AG, Johnson & Johnson, and Pfizer, Inc. are the forerunners in the Multiple Myeloma Market. Companies such as Amgen, Inc., Sanofi S.A., and Bristol Myers Squibb Company are some of the key innovators in Multiple Myeloma Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.

Recent Strategies Deployed in Multiple Myeloma Market

Partnerships, Collaborations and Agreements:

Mar-2022: Sanofi came into collaboration with Blackstone Life Sciences, a US-based private equity firm focused on investing in pharmaceutical, life science, and medical research companies. The collaboration involves the private equity firm contributing up to 300 million euros to advance studies and clinical development programs for the development and delivery of the anti-CD38 antibody Sarclisa focused on treating patients with multiple myeloma.

Jan-2020: Sanofi partnered with Sebia, a France-based provider of clinical protein electrophoresis equipment. The partnership focuses on co-developing treatment for multiple myeloma. The agreement includes, Sebia developing in vitro diagnostic (IVD) tests and acting as its supplier.

Acquisitions and Mergers:

Dec-2022: Johnson & Johnson took over Abiomed, a US-based medical device technology company. The addition of Abiomed advances the acquiring company's MedTech business division, by providing innovational medical technologies. Further, the acquisition broadens Johnson & Johnson's cardiovascular product offerings.

Dec-2021: Baxter acquired Hillrom, a US-based medical device company. The acquisition advances the company's mission to transform healthcare and patient care.

Nov-2021: Pfizer acquired Trillium Therapeutics, a Canada-based clinical-stage immuno-oncology company. The acquisition strengthens the acquiring company's devotion to seeking scientific breakthroughs. Further, the addition of Trillium expands Pfizer's hematology product offerings.

Oct-2021: Amgen completed the acquisition of Teneobio, a US-based biotechnology company. The acquisition of Teneobio broadens the acquiring company's skills and further accelerates its aim to design, build and bring innovations to the markets to better serve their patients. Further, the addition of Teneobio's proprietary bispecific and multispecific antibody technologies perfectly complements Amgen's BiTE platform and its already existing antibody capabilities.

Product Launches and Expansions:

Mar-2023: Teva and Natco together launched extra strengths for the generic version of Revlimid. The medicine is intended to use by adult patients for the cure of multiple myeloma, specific myelodysplastic syndromes, and mantle cell lymphoma. The added strengths reflect the company's devotion to making generic drugs accessible to patients who need them.

Feb-2022: Sandoz, part of Novartis introduced lenalidomide, a generic oncology medicine. The medicine is intended for various haemato-oncology conditions and is available in the form of hard capsules. Lenalidomide is a cost-saving treatment, thereby increasing the treatment's accessibility amongst patients.

Dec-2021: Novartis introduced T-Charge, a CAR-T platform that would act as a base for multiple investigational CAR-T cell therapies. The T-Charge eradicates the need for extended culture time outside the body (ex-vivo), as it primarily happens within a patient's body.

Trials and Approvals:

Oct-2022: The US FDA issued clearance for Johnson & Johnson's Tecvayli, a BCMA-targeted bispecific drug intended for treating patients with refractory or relapsed multiple myeloma. The conditions to be met to use the recently approved drug, patients must have undergone a minimum of four lines of therapy.

Jan-2022: Bristol Myers Squibb received approval for Abecma in Japan. Abecma is a CAR T therapy intended for adult patients with refractory or relapsed (R/R) multiple myeloma. The adult patient should have already received a minimum of three therapies and should have experienced disease progression on the last therapy. Further, the approval demonstrates the company's devotion to catering to the unmet medical needs in Japan.

Dec-2021: U.S. Food and Drug Administration (FDA) approved Amgen's expansion of KYPROLIS to use it in combination with DARZALEX FASPRO, and dexamethasone. The new combination is intended for adult patients with refractory or relapsed multiple myeloma, who have undergone one to three lines of therapy. Further, the combination provides enhanced flexibility and easiness to the patients.

Mar-2020: Sanofi announced FDA approved the use of Sarclisa in combination with dexamethasone and pomalidomide. The combination is intended for the treatment of adults with relapsed refractory multiple myeloma (RRMM), who have already received two therapies. The approval provides patients with hard-to-treat multiple myeloma with a new treatment option.

Scope of the Study

Market Segments covered in the Report:

By End User

  • Hospitals
  • Clinics
  • Others

By Disease Type

  • Active Multiple Myeloma
  • Smoldering Multiple Myeloma

By Drug Type

  • Protease Inhibitors
  • Monoclonal Antibody
  • Chemotherapy
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Novartis AG
  • Bristol Myers Squibb Company
  • Amgen, Inc.
  • AbbVie, Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Baxter International, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Pfizer, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Multiple Myeloma Market, by End User
    • 1.4.2 Global Multiple Myeloma Market, by Disease Type
    • 1.4.3 Global Multiple Myeloma Market, by Drug Type
    • 1.4.4 Global Multiple Myeloma Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition & Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Acquisition and Mergers
    • 3.2.4 Trials and Approvals
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)

Chapter 4. Global Multiple Myeloma Market by End User

  • 4.1 Global Hospitals Market by Region
  • 4.2 Global Clinics Market by Region
  • 4.3 Global Others Market by Region

Chapter 5. Global Multiple Myeloma Market by Disease Type

  • 5.1 Global Active Multiple Myeloma Market by Region
  • 5.2 Global Smoldering Multiple Myeloma Market by Region

Chapter 6. Global Multiple Myeloma Market by Drug Type

  • 6.1 Global Protease Inhibitors Market by Region
  • 6.2 Global Monoclonal Antibody Market by Region
  • 6.3 Global Chemotherapy Market by Region
  • 6.4 Global Others Market by Region

Chapter 7. Global Multiple Myeloma Market by Region

  • 7.1 North America Multiple Myeloma Market
    • 7.1.1 North America Multiple Myeloma Market by End User
      • 7.1.1.1 North America Hospitals Market by Country
      • 7.1.1.2 North America Clinics Market by Country
      • 7.1.1.3 North America Others Market by Country
    • 7.1.2 North America Multiple Myeloma Market by Disease Type
      • 7.1.2.1 North America Active Multiple Myeloma Market by Country
      • 7.1.2.2 North America Smoldering Multiple Myeloma Market by Country
    • 7.1.3 North America Multiple Myeloma Market by Drug Type
      • 7.1.3.1 North America Protease Inhibitors Market by Country
      • 7.1.3.2 North America Monoclonal Antibody Market by Country
      • 7.1.3.3 North America Chemotherapy Market by Country
      • 7.1.3.4 North America Others Market by Country
    • 7.1.4 North America Multiple Myeloma Market by Country
      • 7.1.4.1 US Multiple Myeloma Market
        • 7.1.4.1.1 US Multiple Myeloma Market by End User
        • 7.1.4.1.2 US Multiple Myeloma Market by Disease Type
        • 7.1.4.1.3 US Multiple Myeloma Market by Drug Type
      • 7.1.4.2 Canada Multiple Myeloma Market
        • 7.1.4.2.1 Canada Multiple Myeloma Market by End User
        • 7.1.4.2.2 Canada Multiple Myeloma Market by Disease Type
        • 7.1.4.2.3 Canada Multiple Myeloma Market by Drug Type
      • 7.1.4.3 Mexico Multiple Myeloma Market
        • 7.1.4.3.1 Mexico Multiple Myeloma Market by End User
        • 7.1.4.3.2 Mexico Multiple Myeloma Market by Disease Type
        • 7.1.4.3.3 Mexico Multiple Myeloma Market by Drug Type
      • 7.1.4.4 Rest of North America Multiple Myeloma Market
        • 7.1.4.4.1 Rest of North America Multiple Myeloma Market by End User
        • 7.1.4.4.2 Rest of North America Multiple Myeloma Market by Disease Type
        • 7.1.4.4.3 Rest of North America Multiple Myeloma Market by Drug Type
  • 7.2 Europe Multiple Myeloma Market
    • 7.2.1 Europe Multiple Myeloma Market by End User
      • 7.2.1.1 Europe Hospitals Market by Country
      • 7.2.1.2 Europe Clinics Market by Country
      • 7.2.1.3 Europe Others Market by Country
    • 7.2.2 Europe Multiple Myeloma Market by Disease Type
      • 7.2.2.1 Europe Active Multiple Myeloma Market by Country
      • 7.2.2.2 Europe Smoldering Multiple Myeloma Market by Country
    • 7.2.3 Europe Multiple Myeloma Market by Drug Type
      • 7.2.3.1 Europe Protease Inhibitors Market by Country
      • 7.2.3.2 Europe Monoclonal Antibody Market by Country
      • 7.2.3.3 Europe Chemotherapy Market by Country
      • 7.2.3.4 Europe Others Market by Country
    • 7.2.4 Europe Multiple Myeloma Market by Country
      • 7.2.4.1 Germany Multiple Myeloma Market
        • 7.2.4.1.1 Germany Multiple Myeloma Market by End User
        • 7.2.4.1.2 Germany Multiple Myeloma Market by Disease Type
        • 7.2.4.1.3 Germany Multiple Myeloma Market by Drug Type
      • 7.2.4.2 UK Multiple Myeloma Market
        • 7.2.4.2.1 UK Multiple Myeloma Market by End User
        • 7.2.4.2.2 UK Multiple Myeloma Market by Disease Type
        • 7.2.4.2.3 UK Multiple Myeloma Market by Drug Type
      • 7.2.4.3 France Multiple Myeloma Market
        • 7.2.4.3.1 France Multiple Myeloma Market by End User
        • 7.2.4.3.2 France Multiple Myeloma Market by Disease Type
        • 7.2.4.3.3 France Multiple Myeloma Market by Drug Type
      • 7.2.4.4 Russia Multiple Myeloma Market
        • 7.2.4.4.1 Russia Multiple Myeloma Market by End User
        • 7.2.4.4.2 Russia Multiple Myeloma Market by Disease Type
        • 7.2.4.4.3 Russia Multiple Myeloma Market by Drug Type
      • 7.2.4.5 Spain Multiple Myeloma Market
        • 7.2.4.5.1 Spain Multiple Myeloma Market by End User
        • 7.2.4.5.2 Spain Multiple Myeloma Market by Disease Type
        • 7.2.4.5.3 Spain Multiple Myeloma Market by Drug Type
      • 7.2.4.6 Italy Multiple Myeloma Market
        • 7.2.4.6.1 Italy Multiple Myeloma Market by End User
        • 7.2.4.6.2 Italy Multiple Myeloma Market by Disease Type
        • 7.2.4.6.3 Italy Multiple Myeloma Market by Drug Type
      • 7.2.4.7 Rest of Europe Multiple Myeloma Market
        • 7.2.4.7.1 Rest of Europe Multiple Myeloma Market by End User
        • 7.2.4.7.2 Rest of Europe Multiple Myeloma Market by Disease Type
        • 7.2.4.7.3 Rest of Europe Multiple Myeloma Market by Drug Type
  • 7.3 Asia Pacific Multiple Myeloma Market
    • 7.3.1 Asia Pacific Multiple Myeloma Market by End User
      • 7.3.1.1 Asia Pacific Hospitals Market by Country
      • 7.3.1.2 Asia Pacific Clinics Market by Country
      • 7.3.1.3 Asia Pacific Others Market by Country
    • 7.3.2 Asia Pacific Multiple Myeloma Market by Disease Type
      • 7.3.2.1 Asia Pacific Active Multiple Myeloma Market by Country
      • 7.3.2.2 Asia Pacific Smoldering Multiple Myeloma Market by Country
    • 7.3.3 Asia Pacific Multiple Myeloma Market by Drug Type
      • 7.3.3.1 Asia Pacific Protease Inhibitors Market by Country
      • 7.3.3.2 Asia Pacific Monoclonal Antibody Market by Country
      • 7.3.3.3 Asia Pacific Chemotherapy Market by Country
      • 7.3.3.4 Asia Pacific Others Market by Country
    • 7.3.4 Asia Pacific Multiple Myeloma Market by Country
      • 7.3.4.1 China Multiple Myeloma Market
        • 7.3.4.1.1 China Multiple Myeloma Market by End User
        • 7.3.4.1.2 China Multiple Myeloma Market by Disease Type
        • 7.3.4.1.3 China Multiple Myeloma Market by Drug Type
      • 7.3.4.2 Japan Multiple Myeloma Market
        • 7.3.4.2.1 Japan Multiple Myeloma Market by End User
        • 7.3.4.2.2 Japan Multiple Myeloma Market by Disease Type
        • 7.3.4.2.3 Japan Multiple Myeloma Market by Drug Type
      • 7.3.4.3 India Multiple Myeloma Market
        • 7.3.4.3.1 India Multiple Myeloma Market by End User
        • 7.3.4.3.2 India Multiple Myeloma Market by Disease Type
        • 7.3.4.3.3 India Multiple Myeloma Market by Drug Type
      • 7.3.4.4 South Korea Multiple Myeloma Market
        • 7.3.4.4.1 South Korea Multiple Myeloma Market by End User
        • 7.3.4.4.2 South Korea Multiple Myeloma Market by Disease Type
        • 7.3.4.4.3 South Korea Multiple Myeloma Market by Drug Type
      • 7.3.4.5 Singapore Multiple Myeloma Market
        • 7.3.4.5.1 Singapore Multiple Myeloma Market by End User
        • 7.3.4.5.2 Singapore Multiple Myeloma Market by Disease Type
        • 7.3.4.5.3 Singapore Multiple Myeloma Market by Drug Type
      • 7.3.4.6 Malaysia Multiple Myeloma Market
        • 7.3.4.6.1 Malaysia Multiple Myeloma Market by End User
        • 7.3.4.6.2 Malaysia Multiple Myeloma Market by Disease Type
        • 7.3.4.6.3 Malaysia Multiple Myeloma Market by Drug Type
      • 7.3.4.7 Rest of Asia Pacific Multiple Myeloma Market
        • 7.3.4.7.1 Rest of Asia Pacific Multiple Myeloma Market by End User
        • 7.3.4.7.2 Rest of Asia Pacific Multiple Myeloma Market by Disease Type
        • 7.3.4.7.3 Rest of Asia Pacific Multiple Myeloma Market by Drug Type
  • 7.4 LAMEA Multiple Myeloma Market
    • 7.4.1 LAMEA Multiple Myeloma Market by End User
      • 7.4.1.1 LAMEA Hospitals Market by Country
      • 7.4.1.2 LAMEA Clinics Market by Country
      • 7.4.1.3 LAMEA Others Market by Country
    • 7.4.2 LAMEA Multiple Myeloma Market by Disease Type
      • 7.4.2.1 LAMEA Active Multiple Myeloma Market by Country
      • 7.4.2.2 LAMEA Smoldering Multiple Myeloma Market by Country
    • 7.4.3 LAMEA Multiple Myeloma Market by Drug Type
      • 7.4.3.1 LAMEA Protease Inhibitors Market by Country
      • 7.4.3.2 LAMEA Monoclonal Antibody Market by Country
      • 7.4.3.3 LAMEA Chemotherapy Market by Country
      • 7.4.3.4 LAMEA Others Market by Country
    • 7.4.4 LAMEA Multiple Myeloma Market by Country
      • 7.4.4.1 Brazil Multiple Myeloma Market
        • 7.4.4.1.1 Brazil Multiple Myeloma Market by End User
        • 7.4.4.1.2 Brazil Multiple Myeloma Market by Disease Type
        • 7.4.4.1.3 Brazil Multiple Myeloma Market by Drug Type
      • 7.4.4.2 Argentina Multiple Myeloma Market
        • 7.4.4.2.1 Argentina Multiple Myeloma Market by End User
        • 7.4.4.2.2 Argentina Multiple Myeloma Market by Disease Type
        • 7.4.4.2.3 Argentina Multiple Myeloma Market by Drug Type
      • 7.4.4.3 UAE Multiple Myeloma Market
        • 7.4.4.3.1 UAE Multiple Myeloma Market by End User
        • 7.4.4.3.2 UAE Multiple Myeloma Market by Disease Type
        • 7.4.4.3.3 UAE Multiple Myeloma Market by Drug Type
      • 7.4.4.4 Saudi Arabia Multiple Myeloma Market
        • 7.4.4.4.1 Saudi Arabia Multiple Myeloma Market by End User
        • 7.4.4.4.2 Saudi Arabia Multiple Myeloma Market by Disease Type
        • 7.4.4.4.3 Saudi Arabia Multiple Myeloma Market by Drug Type
      • 7.4.4.5 South Africa Multiple Myeloma Market
        • 7.4.4.5.1 South Africa Multiple Myeloma Market by End User
        • 7.4.4.5.2 South Africa Multiple Myeloma Market by Disease Type
        • 7.4.4.5.3 South Africa Multiple Myeloma Market by Drug Type
      • 7.4.4.6 Nigeria Multiple Myeloma Market
        • 7.4.4.6.1 Nigeria Multiple Myeloma Market by End User
        • 7.4.4.6.2 Nigeria Multiple Myeloma Market by Disease Type
        • 7.4.4.6.3 Nigeria Multiple Myeloma Market by Drug Type
      • 7.4.4.7 Rest of LAMEA Multiple Myeloma Market
        • 7.4.4.7.1 Rest of LAMEA Multiple Myeloma Market by End User
        • 7.4.4.7.2 Rest of LAMEA Multiple Myeloma Market by Disease Type
        • 7.4.4.7.3 Rest of LAMEA Multiple Myeloma Market by Drug Type

Chapter 8. Company Profiles

  • 8.1 Johnson & Johnson
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Segmental &Regional Analysis
    • 8.1.4 Research & Development Expenses
    • 8.1.5 Recent strategies and developments:
      • 8.1.5.1 Trials and Approvals:
      • 8.1.5.2 Acquisition and Mergers:
    • 8.1.6 SWOT Analysis
  • 8.2 Novartis AG
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Segmental and Regional Analysis
    • 8.2.4 Research & Development Expense
    • 8.2.5 Recent strategies and developments:
      • 8.2.5.1 Partnerships, Collaborations, and Agreements:
      • 8.2.5.2 Product Launches and Product Expansions:
  • 8.3 Sanofi S.A.
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Segmental and Regional Analysis
    • 8.3.4 Research & Development Expense
    • 8.3.5 Recent strategies and developments:
      • 8.3.5.1 Partnerships, Collaborations, and Agreements:
      • 8.3.5.2 Trials and Approvals:
  • 8.4 Amgen, Inc.
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Regional Analysis
    • 8.4.4 Research & Development Expenses
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Trials and Approvals:
      • 8.4.5.2 Acquisition and Mergers:
  • 8.5 AbbVie, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Regional Analysis
    • 8.5.4 Research & Development Expense
    • 8.5.5 Recent strategies and developments:
      • 8.5.5.1 Partnerships, Collaborations, and Agreements:
  • 8.6 Baxter International, Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Segmental and Regional Analysis
    • 8.6.4 Research & Development Expense
    • 8.6.5 Recent strategies and developments:
      • 8.6.5.1 Acquisition and Mergers:
  • 8.7 Teva Pharmaceutical Industries Ltd.
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Regional Analysis
    • 8.7.4 Research & Development Expenses
    • 8.7.5 Recent strategies and developments:
      • 8.7.5.1 Product Launches and Product Expansions:
  • 8.8 Pfizer, Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Regional & Segmental Analysis
    • 8.8.4 Research & Development Expense
    • 8.8.5 Recent strategies and developments:
      • 8.8.5.1 Acquisition and Mergers:
  • 8.9 Bristol Myers Squibb Company
    • 8.9.1 Company Overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Regional Analysis
    • 8.9.4 Research & Development Expenses
    • 8.9.5 Recent strategies and developments:
      • 8.9.5.1 Trials and Approvals:
      • 8.9.5.2 Acquisition and Mergers:
  • 8.10. Takeda Pharmaceutical Company Limited
    • 8.10.1 Company Overview
    • 8.10.2 Financial Analysis
    • 8.10.3 Regional Analysis
    • 8.10.4 Research & Development Expense